.001) were higher with non T-cell depleted grafts. Day-100 mortality rate was significantly higher after non-fludarabine than fludarabine containing regimens (65% vs. 24%, respectively p<0.001). Corresponding 3-year adjusted overall survival rates were 13% vs. 52% (p<0.001). In addition, mortality was higher in recipients who were older (>10 years), CMV seropositive and received >20-blood product transfusions pre-BMT. Based on these results significant practice changes are suggested: use of a fludarabine containing conditioning regimen in the context of T cell depleted marrow allografts and earlier referral for transplantation prior to excessive transfusions in patients with marrow failure.
INTRODUCTION
Fanconi anemia (FA) is a genetically and phenotypically heterogeneous disorder characterized by congenital malformations, progressive marrow failure and marked predisposition to leukemia and epithelial malignancies. [1] [2] [3] [4] [5] [6] [7] While the basic genetic and biochemical defects responsible are now being elucidated, allogeneic hematopoietic stem transplantation still remains the only known treatment modality that can correct the hematological defects associated with FA.
Importantly, hematologic abnormalities occur in virtually all patients with FA at a median age of 7 years (range, birth to 41 years). 4, 5 Based on clinical data in the International Fanconi Anemia Registry (IFAR, n=754 patients), the cumulative incidence of bone marrow failure by age 40 is 90%. Initial hematologic findings are most commonly pancytopenia; however, some patients present with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). The cumulative incidence of MDS or AML by age 40 is 33%. 4, 5 In 2000, the results of a retrospective multi-center study of 69 unrelated donor BMT facilitated through the European Group for Blood and Marrow Transplantation (EBMT) and the European FA Registry were reported by Guardiola et al. 8 The 3-year probability of survival was 33%. The primary causes of death were acute graft-versus-host disease (GVHD, n=18), primary or secondary graft failure (n=13), chronic GVHD (n=4), infections (n=7) and veno-occlusive disease of the liver (n=1). In this study, presence of three or more extramedullary congenital malformations, use of androgens prior to BMT, positive recipient cytomegalovirus serology and use of a female donor were independent risk factors associated with poor survival. Because of the high risk of transplant-related mortality (TRM) from graft failure and GVHD, unrelated donor transplantation has not been generally recommended until failure of other treatment modalities, such as use of androgens and transfusions. However, early reports 2,9,10 suggest The NMDP retrospectively obtained consent for study participation from surviving patients or their parent/legal guardian for transplantations it facilitated during the study period; the NMDP IRB waived consent for patients who had died before soliciting consent. To address introduction of bias by inclusion of only a proportion of surviving patients (those consenting) but all deceased recipients, a sample of deceased patients was selected using a weighted randomized scheme that adjusts for over-representation of deceased patients in the consented cohort. 11 This weighted randomized scheme was developed based on all survivors in the NMDP database. A logistic regression model was fit to identify the factors that predicted whether a patient had consented to use of data collected by the NMDP. This analysis found that the following factors were associated with the likelihood of a patient consenting: age at transplantation, disease, race, sex, cytomegalovirus serologic status and country of transplantation (U.S. vs. non-U.S.). Using estimated consenting probabilities from this model based on characteristics of dead patients, the biased coin method of randomization was performed to determine which of the dead patients likely would have consented to participate had they been alive. Thus this procedure includes the For personal use only. on November 12, 2017 . by guest www.bloodjournal.org From pre-consented dead patients at the same probability as surviving patients who consented to participate. Thus, of the 120 patients who met the eligibility criteria for this study, 98 were included after this adjustment.
End points
Neutrophil recovery was defined as achieving an absolute neutrophil count (ANC) of at least 500 cells per cubic millimeter for 3 consecutive days; platelet recovery was defined as achieving at least 20,000 platelets per cubic millimeter, unsupported by transfusions for at least 7 days.
Diagnosis of acute and chronic GVHD was based on local institutional criteria with overall grade of acute GVHD assigned retrospectively by the CIBMTR based on stage of involvement reported for each individual organ. 12, 13 Transplant-related mortality was defined as any cause of death other than recurrent leukemia. Surviving patients were censored at date of last contact.
Statistical analysis
Variables related to patient, disease and transplant characteristics are shown in Table 1 . The probability of day-100 mortality and overall survival were calculated using the Kaplan-Meier estimator. 14 For analysis of survival, death from any cause was considered an event and outcome-data on patients alive were censored at 36-months post-transplantation. The probabilities of neutrophil and platelet recovery, acute and chronic GVHD and transplant-related mortality were calculated using the cumulative-incidence-function method. 15 For neutrophil and platelet recovery and GVHD, death without an event (hematopoietic recovery or GVHD) was the competing event. For transplant-related mortality recurrent leukemia was the competing event.
Confidence intervals [CI] were calculated with the use of a log-transformation. 15 The p-value for comparison of probabilities of hematopoietic recovery, GVHD, transplant-related mortality, day-100 mortality and overall survival at any given time point was calculated using the point-wise pFor personal use only. on November 12, 2017 . by guest www.bloodjournal.org From value estimator. Cox regression models were built for analysis of risk factors for GVHD, early mortality (within 100 days after transplantation), transplant-related and overall mortality and logistic regression models were built for analysis of risk factors for neutrophil and platelet recovery at day-28 and 1-year, respectively. 15, 16 Ninety-six patients were evaluable for analysis of risk factors for transplant-related, early and overall mortality. Two patients were excluded because data on GVHD prophylaxis was not available. For personal use only. on November 12, 2017. by guest www.bloodjournal.org From
RESULTS

Patients
Patient-, disease-and transplant characteristics are shown in Table 1 Patient-, disease-and transplant characteristics of recipients of fludarabine-based and nonfludarabine conditioning regimens were similar except that recipients of fludarabine-containing regimens were more likely to have a good performance score (90-100) at transplantation (91% vs. 64%, p=0.002) and received T-cell depleted grafts (96% vs. 51%, p<0.001). Potential differences in the proportion of patients with DEB T-cell mosaicism between groups could not be determined as data on DEB mosaicism was more likely available (93%) in recipients of fludarabine and less likely available (60%) in recipients of non-fludarabine regimens.
Neutrophil and Platelet recovery
Seventy-seven of 98 patients achieved neutrophil recovery. Median time to recovery was 11 days (range 8-27) with an overall probability of 78% (95% CI 68-85) by day-28. Among the 79 patients for whom data on DEB T-cell mosaicism was available, the probability of neutrophil recovery differed by type of conditioning regimen and DEB T-cell mosaicism (Table 2a , Figure   1a , 1b). The day-28 probability of recovery was higher in recipients of a fludarabine versus a non-fludarabine containing regimen (89% vs. 69%, p=0.02). Among recipients of fludarabinecontaining regimens, probability of recovery was similar in patients with and without DEB T-cell mosaicism. In contrast, the probability of recovery differed in recipients of non-fludarabine regimens with probable greater engraftment in those without DEB T-cell mosaicism (89% vs. 52%, odds ratio [OR] 0.14, 95% CI 0.02-1.23, p=0.076).
Forty-four of 90 evaluable patients achieved platelet recovery. Median time to recovery was 36 days (range 15-148) with an overall probability of 49% (95% CI 38-59)% at 1-year. The probability of platelet recovery also differed by conditioning regimen (Table 2b) . The day-100 probability of platelet recovery was higher in recipients of fludarabine than non-fludarabine containing regimens (74% vs. 23%, p<0.001). An effect of DEB T-cell mosaicism was not observed on platelet recovery. Recovery was more likely in patients who had received ≤20 blood product transfusions prior to transplantation.
Acute and Chronic GVHD
Thirty of 96 patients developed grade 2-4 acute GVHD. Of these, 28 developed acute GVHD within 100 days for an overall day-100 probability of 29% (95% CI 20-38). Grade 2-4 acute GVHD was statistically significantly higher in recipients of a non-fludarabine containing regimen who received a non T-cell depleted graft (RR 4.29, 95% CI 1.82-10.10, p<0.001). The day-100 probabilities of grade 2-4 acute GVHD were 70% and 21% after transplantation of non T-cell depleted and T-cell depleted bone marrow grafts after a non-fludarabine containing regimen, respectively. The corresponding probability after a fludarabine-containing regimen was 16%. Seventeen patients developed grade 3-4 acute GVHD. Most patients (n=13) who developed grade 3-4 acute GVHD received non T-cell depleted grafts. Sixteen of 55 patients surviving beyond 90 days developed chronic GVHD for an overall 3-year probability of 31% (95% CI 19-44). There were no statistically significant differences in risks of chronic GVHD by conditioning regimen or GVHD prophylaxis.
Transplant-related mortality
Risks of transplant-related mortality were statistically significantly higher after a nonfludarabine containing regimen with a T-cell depleted graft (RR 3.69, 95% CI 1.76-7.68, p<0.001) or non T-cell depleted graft (RR 3.87, 95% CI 1.94-7.73, p<0.001) compared to fludarabine containing regimens. Transplant-related mortality rates were higher in patients who were CMV positive by serology and received bone marrow grafts from donors who were also CMV positive (RR 5.01, 95% CI 2.08-12.09, p<0.001) and patients who received >20 units of blood product transfusions prior to transplantation (RR 2.48, 95% CI 1.30-4.75, p=0.006). The 3-year probabilities of treatment-related mortality were 47% (95% CI 31-60) and 81% (95% CI 67-89) in recipients of fludarabine-containing and non-fludarabine containing regimens, respectively (p<0.001).
Early mortality
Risks of early mortality were statistically significantly higher after a non-fludarabine containing regimen, in patients who were CMV seropositive and patients aged >10 years at transplantation (Table 3a) . The day-100 probability of mortality after a fludarabine versus a non-fludarabine containing regimen was 24% and 65%, respectively (p<0.001). Early death occurred in 11 patients after fludarabine and 34 after non-fludarabine containing regimens. Causes of early mortality in recipients of fludarabine and non-fludarabine containing regimens were graft failure (n=5 and n=13), GVHD (n=0 and n=9), interstitial pneumonitis (n=1 and n=1), opportunistic infection (n=2 and n=8), and organ failure (n=3 and n=3), respectively.
Overall survival
Risks of overall mortality were statistically significantly higher after a non-fludarabine containing regimen, in patients who were CMV seropositive and received bone marrow grafts from donors who were also CMV seropositive and patients who received >20 units of red blood cells prior to transplantation (Table 3b ). The 3-year probabilities of overall survival after fludarabine-containing and non-fludarabine regimens were 52% and 13%, respectively (p<0.001) after adjusting for number of prior red blood cell transfusions and CMV sero-status (Figure 2 ). Beyond day 100, 21 patients died; 10 received fludarabine and 11, non-fludarabine containing regimens. Causes of mortality in recipients of fludarabine and non-fludarabine containing regimens were graft failure (n=2 and n=6), GVHD (n=5 and n=3), interstitial pneumonitis (n=0 and n=1), organ failure (n=2 and n=0) and recurrent leukemia (n=1 and n=1), respectively. There
For personal use only. on November 12, 2017. by guest www.bloodjournal.org From were no statistically significant differences in causes of death by conditioning regimen or HLA disparity.
DISCUSSION
BMT is the only current treatment with curative potential for the marrow failure syndrome that characterizes FA. Early experiences with BMT for the treatment of marrow failure were poor, primarily the result of excessive regimen-related toxicity, graft failure and severe acute GVHD 2, 8, [17] [18] [19] Early conditioning regimens were modeled after those for patients with acquired aplastic anemia, administering cyclophosphamide alone or in combination with busulfan or total body irradiation (TBI). Severe toxicities, including cardiac myopathy, gastrointestinal hemorrhage, hemorrhagic cystitis and radiation skin burns were commonly reported. This clinical experience prompted in vitro laboratory studies that confirmed the hypersensitivity of FA cells to cyclophosphamide and TBI. [20] [21] [22] As a result of these in vitro studies, Gluckman et al. 22, 23 proposed the use of low dose cyclophosphamide and thoracoabdominal irradiation in the treatment of FA patients. This approach subsequently proved to be a major advance in the treatment of FA patients with HLA matched sibling donors. Unfortunately, this therapy was not sufficient for consistent engraftment in recipients of unrelated donor bone marrow transplantation with graft rejection exceeding 20% in most series.
2,8,18,23
To date, there have only been few registry reports on the efficacy of unrelated donor BMT in FA. 8, 17 In an attempt to extend these observations as well as specifically assess the impact of fludarabine, which could not be evaluated in the European report 8 that in general predated the use of fludarabine, we evaluated the impact of unrelated donor BMT for FA at U.S. centers as facilitated by the NMDP. In contrast to the EBMT report 8 in which a higher mortality was
For personal use only. on November 12, 2017. by guest www.bloodjournal.org From observed in patients with ≥3 congenital malformations, prior exposure to androgens and a female donor, the current series identified 3 different factors associated with improved survival: use of fludarabine in the preparative therapy, younger recipient age at BMT (≤10 years), and exposure to fewer than 20 blood product transfusions. Recipient CMV negative sero-status was found to be associated with improved survival in both analyses. We were not able to access the impact of congenital malformations due to incomplete data. Importantly, this is the first report to document the benefit of fludarabine in patients with FA in terms of hematopoietic recovery and survival. Fludarabine is optimal in patients with FA as it is an antimetabolite with profound immunosuppressive properties. As FA cells are hypersensitive to DNA cross-linking agents, agents like cyclophosphamide have a relatively tight therapeutic window associated with a high rate of excess non-hematopoietic toxicities. As such, low dose cyclophosphamide with or without limited field irradiation or low dose TBI has been inadequate for consistent engraftment. As reported by Guardiola et al. 8 and others, 2, 10, 18, 19 we observed an excess rate of graft failure in recipients not treated with fludarabine. Incorporation of fludarabine into the preparative regimen has markedly improved the probability of engraftment without increasing the risk of regimen related end organ toxicity, leading to improved survival.
Over the past 5 years, there has been increasing recognition of somatic mosaicism in patients with FA. While it has been postulated that somatic mosiacism may delay the onset of hematopoietic failure in patients with FA, it is clear that it does not always prevent marrow failure or progression to MDS or leukemia. [24] [25] [26] While it remains to be proven as to whether the presence of DEB-resistant cells generally reflects a genetic reversion in a stem cell, there is some data that suggest that the presence of any DEB resistant cells may be associated with a higher risk of graft failure. 2, 10 In the present series, neutrophil recovery was not influenced by the While not proof, this observation suggests that the high frequency of graft rejection observed in recipients of low dose cyclophosphamide and radiation may be due to incomplete ablation of DEB-resistant lymphocytes and that the addition of fludarabine overcame this obstacle.
In reports by Guardiola et al. 8 and others, 2,17,18 a major limitation to the success of unrelated donor BMT has been GVHD. In this series, T-cell depletion of the marrow graft reduced the risk of acute GVHD and in recipients of fludarabine-based preparatory regimens, T-cell depletion did not have an adverse effect on hematopoietic recovery or overall survival. As 96% of recipients of fludarabine-based preparatory regimen received a T-cell depleted bone marrow graft it is possible that the additional immunosuppression from fludarabine may have overcome any adverse effect on hematopoietic recovery often observed in recipients of a T-cell depleted allograft. 27 As a history of GVHD has been associated with an increased risk of malignancy in FA patients at a median of 8 years, 28 strategies to reduce the risk of GVHD and improve overall survival, such as T-cell depletion with fludarabine-based preparatory regimens, are an important part of the treatment plan.
Although excess transfusion exposure was associated with higher mortality we did not observe a greater risk of graft failure. It is possible that transfusion exposure is a surrogate marker for factors that go along with delayed transplant, e.g., infection exposure and hemochromatosis and may explain its association with higher mortality. Data on transfusion exposure are unknown for approximately a third of patients and we do not have data on pre-
hemochromatosis. Thus insufficient data are available to explain the observed association of excess transfusion exposure and greater risk of mortality. Nonetheless, the data would argue for earlier transplantation in those with marrow failure, prior to excess transfusion exposures.
As in other transplant studies, age at BMT has an effect on survival. Older recipients (>10 years) had higher early mortality. This effect however was not observed beyond the first 100 days after transplantation. CMV seropositivity of the recipient also had an adverse effect on both early and overall survival. Guardiola and colleagues 8 also observed higher mortality in patients who are seropositive for cytomegalovirus and as in the current series were unable to provide a clear explanation.
We did not observe a significant correlation between complementation groups and hematopoietic recovery or mortality. Data on complementation group, however, was available for only 56% of patients and small numbers may have limited our ability to detect a meaningful effect. In this series, androgens and HLA disparity had no demonstrable effect on transplantoutcomes. It is also possible that the use of fludarabine may have sufficiently improved outcomes to mask any deleterious effect of androgens and HLA mismatch that has been observed previously. However, despite this observation, larger studies in unrelated donor BMT clearly demonstrate the negative effect of HLA mismatch on survival. [29] [30] [31] [32] [33] Therefore, matching between recipient and donor using high resolution allele level HLA typing represents the current standard of care. 32, 33 As fludarabine has been used almost exclusively after 1998, we were unable to evaluate the effect of year of transplantation, a surrogate for advances in supportive care, on mortality after transplantation. For personal use only. on November 12, 2017. by guest www.bloodjournal.org From
